5F-AB-PINACA

5F-AB-PINACA

Systematic (IUPAC) name
N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-(4-fluorobutyl)indazole-3-carboxamide
Clinical data
Legal status	CA: Schedule II DE: Anlage II (Prohibited)
Identifiers
CAS Number	1800101-60-3
PubChem	CID 71301473
UNII	3L83B2298V
Chemical data
Formula	C17H23FN4O2
Molar mass	334.40 g·mol^−1
SMILES CC(C)[C@H](NC(=O)c1nn(CCCCF)c2ccccc12)C(N)=O
InChI InChI=1S/C17H23FN4O2/c1-11(2)14(16(19)23)20-17(24)15-12-7-3-4-8-13(12)22(21-15)10-6-5-9-18/h3-4,7-8,11,14H,5-6,9-10H2,1-2H3,(H2,19,23)(H,20,24)/t14-/m0/s1 Key:VOMPUVOJBVRDRY-AWEZNQCLSA-N

5F-AB-PINACA is an indazole-based synthetic cannabinoid that is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication, and has been sold online as a designer drug.^[1][2]

5F-AB-PINACA has been reported to be a potent agonist of the CB₁ receptor and CB₂ receptor with EC₅₀ values of 0.48 nM and 2.6 nM respectively.^[3] Its metabolism has been described in literature.^[4][5]

Legality

China

As of October 2015 5F-AB-PINACA is a controlled substance in China.^[6]

Germany

5F-AB-PINACA is an Anlage II controlled substance in Germany as of May 2015.^[7]

Singapore

It is also controlled under the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore as of May 2015.^[8]

See also

• 5F-ADB
• 5F-AMB
• 5F-CUMYL-PINACA
• AB-FUBINACA
• AB-CHFUPYCA
• AB-PINACA
• ADB-CHMINACA
• ADB-FUBINACA
• ADB-PINACA
• ADBICA
• APICA
• APINACA
• MDMB-CHMICA
• PX-3

References

1. "Patent WO/2009/106980 - Indazole derivatives".
2. "5F-AB-PINACA". Cayman Chemical. Retrieved 5 July 2015.
3. Samuel D Banister, Michael Moir, Jordyn Stuart, Richard C Kevin, Katie E Wood, Mitchell Longworth, Shane M Wilkinson, Corinne Beinat, Alxendra S Buchanan, Michelle Glass, Mark Connor, Iain S McGregor, Michael Kassiou (July 2015). "The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA". ACS Chemical Neuroscience 6: 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
4. Ariane Wohlfarth, Marisol S. Castaneto, Mingshe Zhu, Shaokun Pang, Karl B. Scheidweiler, Robert Kronstrand, Marilyn A. Huestis (May 2015). "Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA". The AAPS Journal 17 (3): 660–677. doi:10.1208/s12248-015-9721-0. PMID 25721194.
5. Moonhee Jang, Ilchung Shin, Jihyun Kim, Wonkyung Yang (February 2015). "Simultaneous quantification of 37 synthetic cannabinoid metabolites in human urine by liquid chromatography-tandem mass spectrometry". Forensic Toxicology 33: 221–234. doi:10.1007/s11419-015-0265-x.
6. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
7. "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)" (in German). Retrieved 5 July 2015.
8. "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Retrieved 24 July 2015.